Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates
Provided By GlobeNewswire
Last update: Nov 6, 2024
Q3 2024 Total Revenue of $141.5M, a 37% Increase Year-over-Year
Galafold® Q3 Revenue of $120.4M, up 20% Year-over-Year
Read more at globenewswire.com
